3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 3
1
Phase 2
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
309
Carcinoma, Non-Small-Cell Lung
281
Prostatic Neoplasms
160
Colorectal Neoplasms
155
Carcinoma, Hepatocellular
144
Neoplasms
134
Leukemia, Myeloid, Acute
132
Lung Neoplasms
115
Squamous Cell Carcinoma of Head and Neck
108
Multiple Myeloma
103
Triple Negative Breast Neoplasms
102
Recurrence
99
Pancreatic Neoplasms
93
Stomach Neoplasms
92
Ovarian Neoplasms
87
Neoplasm Metastasis
87
Lymphoma, Large B-Cell, Diffuse
81
Sarcoma
70
Precursor Cell Lymphoblastic Leukemia-Lymphoma
67
Esophageal Neoplasms
67
Uterine Cervical Neoplasms
66
Melanoma
65
Brain Neoplasms
65
Rectal Neoplasms
62
Head and Neck Neoplasms
62
Glioblastoma
60
Carcinoma, Renal Cell
57
Myelodysplastic Syndromes
55
Lymphoma
55
Esophageal Squamous Cell Carcinoma
54
Interventions
ASP3662
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
Diabetes Mellitus, Type 2
×
Clear all
NCT07296484
2026-05-12
CAPTAIN-T2D
Sparrow Pharmaceuticals
Phase 2
Recruiting
1,500 enrolled